Grifols, S.A.
Grifols operates as a plasma therapeutic company globally, providing various medical products including immunoglobulins, albumin, clotting factors, antithrombin III, and biological sealants. It also markets diagnostic testing equipment, reagents, and pharmaceutical products. The company is involved in research activities and develops new products, some of which are in clinical development stages.
Overview
Strengths
- Price to book ratio (0.92) is lower than the sector mean (8.32).
- EV/EBITDA (8.73) is lower than the sector mean (21.51).
- EV/EBIT (12.77) is lower than the sector mean.
- Price to free cash flow (10.17) is lower than the sector mean.
- Strong EBITDA Margin of 21.23%.
Weaknesses
- With a depreciation Potential of -29.61%, based on our fundamental analysis, it suggests the stock may be overvalued.
- The company has high debt. Net Debt to EBITDA Ratio (5.20) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (6.08%) is significantly lower than the sector mean (16.32%).
Key Financial Data
| Indicator | Value |
|---|
| PER | 34.4 |
| EV/EBITDA | 8.7 |
| Price/Free Cash Flow' | 10.2 |
| ROIC | 6.1% |
| Net Debt/EBITDA | 5.2 |